Andrea E. Doak

Resistance Mechanisms to Targeted Therapies in <i>ROS1</i> + and <i>ALK</i> + Non–small Cell Lung Cancer

Caroline E. McCoach, Anh T. Le, Katherine Gowan et al. · Clinical Cancer Research · 2018 · 246 citations

Medicine, Molecular Genetics, Oncology +17

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

Sarah K. Nelson-Taylor, Anh T. Le, Minjae Yoo et al. · Molecular Cancer Therapeutics · 2017 · 81 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Adriana Estrada‐Bernal, Anh T. Le, Andrea E. Doak et al. · Clinical Cancer Research · 2020 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract A157: Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions

Adriana Estrada‐Bernal, Andrea E. Doak, Anh T. Le et al. · Molecular Cancer Therapeutics · 2018 · 20 citations

Medicine, Oncology, Pharmacology +17

Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death

Joshua M. Marcus, Russell T. Burke, Andrea E. Doak et al. · Cell Cycle · 2018 · 17 citations · Full text

Life Sciences, Molecular Biology, Oncology +17